EP0633943A4 - Therapie genique utilisant des vecteurs viraux cibles. - Google Patents

Therapie genique utilisant des vecteurs viraux cibles.

Info

Publication number
EP0633943A4
EP0633943A4 EP93908659A EP93908659A EP0633943A4 EP 0633943 A4 EP0633943 A4 EP 0633943A4 EP 93908659 A EP93908659 A EP 93908659A EP 93908659 A EP93908659 A EP 93908659A EP 0633943 A4 EP0633943 A4 EP 0633943A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
viral vectors
targeted viral
targeted
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93908659A
Other languages
German (de)
English (en)
Other versions
EP0633943A1 (fr
Inventor
Alexander T Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0633943A1 publication Critical patent/EP0633943A1/fr
Publication of EP0633943A4 publication Critical patent/EP0633943A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP93908659A 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles. Withdrawn EP0633943A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40748 1979-05-21
US86279592A 1992-04-03 1992-04-03
US862795 1992-04-03
US4074893A 1993-03-29 1993-03-29
PCT/US1993/002957 WO1993020221A1 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles

Publications (2)

Publication Number Publication Date
EP0633943A1 EP0633943A1 (fr) 1995-01-18
EP0633943A4 true EP0633943A4 (fr) 1997-05-02

Family

ID=26717389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93908659A Withdrawn EP0633943A4 (fr) 1992-04-03 1993-03-31 Therapie genique utilisant des vecteurs viraux cibles.

Country Status (5)

Country Link
EP (1) EP0633943A4 (fr)
JP (1) JPH07505773A (fr)
AU (1) AU3940293A (fr)
CA (1) CA2133411A1 (fr)
WO (1) WO1993020221A1 (fr)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
AU689755B2 (en) * 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
EP0746625B1 (fr) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Particules vectorielles pouvant etre ciblees
ATE200105T1 (de) * 1994-05-13 2001-04-15 Chiron Corp Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
WO1997024453A1 (fr) * 1995-12-28 1997-07-10 Chiron Corporation Polypeptides chimeres de surface virale, specifiques d'un recepteur, pour l'incorporation et l'interiorisation d'une particule et d'un virus dans des cellules cibles
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
IL129922A0 (en) 1996-11-15 2000-02-29 Canji Inc Tissue specific expression of retinoblastoma protein
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
EP2008664B1 (fr) 1997-04-10 2012-08-29 University Of Southern California Protéines modifiées qui lient des composants de la matrice extracellulaire
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
EP2308996A1 (fr) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Applications therapeutiques et diagnostiques basées sur le role des gêne cxcr-4 et SDF-1 dans l'oncogénèse
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5269800A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in allergy cells
EP1230349B1 (fr) 1999-11-18 2007-06-13 Dendreon Corporation Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
CN1757724B (zh) 1999-12-10 2014-06-11 茵维特罗根公司 具有独特特异性的多个重组位点在重组克隆中的用途
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO2001096528A2 (fr) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP1383884A4 (fr) 2001-03-22 2004-12-15 Dendreon Corp Molecules d'acide nucleique codant la serine protease cvsp14, polypeptides codes et procedes
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
WO2002092841A2 (fr) 2001-05-14 2002-11-21 Dendreon San Diego Llc Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
WO2003002746A2 (fr) 2001-06-29 2003-01-09 Novartis Ag Methode de criblage de perv et son utilisation
AU2002358631A1 (en) 2001-11-26 2003-06-10 Hybrigenics Protein-protein interactions in human immunodeficiency virus
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
WO2004016750A2 (fr) 2002-08-14 2004-02-26 Macrogenics, Inc. Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
EP2218779A1 (fr) 2002-12-16 2010-08-18 Halozyme, Inc. Glycoprotéine de chondroitinase humaine (chasegp), son procédé de préparation et compositions pharmaceutiques le comportant
EP2368578A1 (fr) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
MXPA05007615A (es) 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
US8021833B2 (en) 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP2302040A1 (fr) 2003-06-13 2011-03-30 University Of Medicine And Dentistry Of New Jersey Utilisation d'ARNm interférase en médecine
WO2005010040A1 (fr) 2003-07-15 2005-02-03 Barros Research Institute Antigene eimeria tenella utilise dans l'immunotherapie de la coccidiose
EP1668111A4 (fr) 2003-08-08 2008-07-02 Genenews Inc Biomarqueurs d'osteoarthrite et leurs utilisations
US20050048617A1 (en) 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
CA2540529C (fr) 2003-10-03 2012-03-13 Vib Vzw Moyens et procedes de recrutement et d'identification de celles souches
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
CN1926551B (zh) 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
EP1786463A4 (fr) 2004-03-26 2009-05-20 Human Genome Sciences Inc Anticorps contre le recepteur nogo
CN101426489A (zh) 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
CA2565450C (fr) 2004-05-07 2018-03-06 Gyorgy Petrovics Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
EP1769078A1 (fr) * 2004-07-01 2007-04-04 VIRxSYS Corporation Lignee cellulaire d'encapsidation de vecteurs
CA2574709A1 (fr) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Traitement du dysfonctionnement renal et du myelome multiple a l'aide de composes pacap
WO2006047639A2 (fr) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2008525479A (ja) 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
EP1869192B1 (fr) 2005-03-18 2016-01-20 MedImmune, LLC Rearrangement de l'infrastructure d'anticorps
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
EP1951908B1 (fr) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Méthodes associées au fgf2 pour diagnostiquer et traiter une dépression
IN2014CN04406A (fr) 2006-03-30 2015-09-04 Ptc Therapeutics Inc
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
EP2074225B1 (fr) 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
EP2064335A4 (fr) 2006-10-16 2011-03-30 Medimmune Llc Molécules ayant des demi-vies réduites, compositions et leurs utilisations
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
RU2493167C2 (ru) 2006-12-18 2013-09-20 Дженентек, Инк. АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
CA2691434C (fr) 2007-06-21 2020-07-21 Macrogenics, Inc. Di-anticorps covalents et leurs utilisations
AU2008269689A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
HUE029925T2 (en) 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
CA2726845C (fr) 2008-06-04 2017-09-26 Macrogenics, Inc. Anticorps a liaison alteree a fcrn et leurs procedes d'utilisation
KR101442323B1 (ko) 2008-09-07 2014-09-25 글라이코넥스 인코포레이티드 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2010072684A1 (fr) 2008-12-22 2010-07-01 Universität Regensburg Utilisation de la protéine norrin dans le traitement de maladies associées à une augmentation de l'activité de tgf-bêta
CN102459576B (zh) 2009-04-27 2015-04-01 渥太华医院研究所 用于调节干细胞的组合物和方法及其应用
WO2010141329A1 (fr) 2009-06-01 2010-12-09 Medimmune, Llc Molecules a demi-vie prolongee et utilisations associees
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
CN102711772A (zh) 2009-10-16 2012-10-03 奥克兰联合服务有限公司 Artemin拮抗剂的抗肿瘤用途
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
WO2011057188A1 (fr) 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Anticorps anti-cd20 canins
CN102892778B (zh) 2010-02-19 2018-06-08 列日大学 用于治疗甲型流感病毒诱发的疾病、编码经修饰的Mx蛋白的多核苷酸、蛋白和转基因动物
EP2591000B1 (fr) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anticorps anti-virus respiratoire syncytial (rsv) humain et procédés d'utilisation
WO2012013249A1 (fr) 2010-07-30 2012-02-02 Université de Liège Protéine 1 de la matrice dentinaire (dmp1) pour l'utilisation dans des compositions pharmaceutiques
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
US10130687B2 (en) 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
BR112014006321A2 (pt) 2011-09-16 2017-04-11 Fate Therapeutics Inc composições de wnt e usos terapêuticos de tal composição
AU2012321103B2 (en) 2011-09-16 2016-05-12 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AU2013285537B2 (en) 2012-07-02 2017-10-12 Medizinische Universitat Wien Complement split product C4d for the treatment of inflammatory conditions
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014120975A1 (fr) 2013-02-01 2014-08-07 California Institute Of Technology Immunocontraception à médiation par un anticorps
EP3450571B1 (fr) 2014-02-24 2023-04-05 Celgene Corporation Procédés d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
EP3142700B1 (fr) 2014-05-16 2021-03-03 Medimmune, LLC Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
KR102641268B1 (ko) 2014-07-17 2024-02-27 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
IL252131B2 (en) 2014-11-17 2023-04-01 Adicet Bio Inc Transgenic gamma delta T cells
US10729790B2 (en) 2015-05-26 2020-08-04 Salk Institute For Biological Studies Motor neuron-specific expression vectors
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
US20190145961A1 (en) 2016-04-20 2019-05-16 Washington University Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
MX2018013864A (es) 2016-05-12 2019-06-10 Adicet Bio Inc Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
MX2020005005A (es) 2017-11-15 2020-08-27 Adicet Bio Inc Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
CA3126896A1 (fr) 2018-12-03 2020-06-11 Adicet Bio Inc. Methodes d'expansion selective in vivo de populations de lymphocytes t gamma delta et compositions associees
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
EP4084819A1 (fr) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap administrée localement pour favoriser la santé parondontale
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
WO2022157548A1 (fr) 2021-01-24 2022-07-28 Forrest Michael David Inhibiteurs d'utilisations cosmétiques et thérapeutiques d'atp synthase
US20240352456A1 (en) 2021-05-13 2024-10-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating sickle cell diseases
EP4373528A2 (fr) 2021-07-19 2024-05-29 New York University Compositions de vecteurs viraux adéno-associés et méthodes de promotion de la régénération musculaire
US20250003978A1 (en) 2021-10-15 2025-01-02 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
WO2023081167A2 (fr) 2021-11-02 2023-05-11 The Regents Of The University Of California Mutants de p-sélectine et modulation de signalisation médiée par intégrine
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
WO2023146807A1 (fr) 2022-01-25 2023-08-03 The Regents Of The University Of California Mutants de vegf et modulation de signalisation médiée par intégrine
US20250206796A1 (en) 2022-04-13 2025-06-26 The Regents Of The University Of California Use of viral il-6 in cancer therapy
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
EP4514834A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation
EP4514821A1 (fr) 2022-04-28 2025-03-05 Immatics US, Inc. Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
EP4554969A1 (fr) 2022-07-15 2025-05-21 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène
WO2025096649A1 (fr) 2023-11-01 2025-05-08 Immatics US, Inc. Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992014829A1 (fr) * 1991-02-19 1992-09-03 The Regents Of The University Of California Particules virales agissant sur une gamme d'hotes modifiee
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique
WO1993014188A1 (fr) * 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. MARTIN ET AL.: "Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurivirulent for mice", EMBO J., vol. 7, no. 9, September 1988 (1988-09-01), OXFORD UNIVERSITY PRESS,GB;, pages 2839 - 2847, XP002025309 *
B. GOUD ET AL.: "Antibody-mediated binding of a murine ecotropic miloney retroviral vector to human cells allows internalization but not the establishment of the proviral state", VIROLOGY, vol. 163, no. 3, March 1988 (1988-03-01), ACADEMIC PRESS, INC.,NEW YORK, US, pages 251 - 254, XP000613633 *
DONG J ET AL: "A CHIMERIC AVIAN RETROVIRUS CONTAINING THE INFLUENZA VIRUS HEMAGGLUTININ GENE HAS AN EXPANDED HOST RANGE", JOURNAL OF VIROLOGY, vol. 66, no. 12, 1 December 1992 (1992-12-01), pages 7374 - 7382, XP002011560 *
HIROSHI NEDA ET AL: "CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA VIRUS RESULTS IN REDIRECTION OF ITS TARGET CELL SPECIFICITY", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991 (1991-08-05), pages 14143 - 14146, XP000612122 *
S.D. LONDON ET AL.: "Infectious enveloped RNA virus antigenic chimeras", PROC. NATL.ACAD SCI., vol. 89, January 1992 (1992-01-01), NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 207 - 211, XP002025310 *
See also references of WO9320221A1 *

Also Published As

Publication number Publication date
EP0633943A1 (fr) 1995-01-18
AU3940293A (en) 1993-11-08
WO1993020221A1 (fr) 1993-10-14
CA2133411A1 (fr) 1993-10-14
JPH07505773A (ja) 1995-06-29

Similar Documents

Publication Publication Date Title
AU3972893A (en) Gene therapy using the intestine
AU699706C (en) Improved vectors for gene therapy
EP0554376A4 (en) Dna construct for providing rna therapy
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
GB9524973D0 (en) Viral vectors
EP0625049A4 (fr) Transfert de genes ex vivo.
AU2552795A (en) Safe vectors for gene therapy
EP0666752A4 (fr) Microemulsions therapeutiques.
EP0679716A4 (fr) Signature genique.
IL110284A0 (en) Viral vectors and their use in gene therapy
AU3434393A (en) Targeted virus
GB9622500D0 (en) Therapeutic gene
AU6014094A (en) Episomal vectors for gene therapy
AU1768192A (en) Rna delivery vector
ZA961849B (en) Method of purification of recombinant viral vectors containing a therapeutic gene.
EP0623171A4 (fr) Molecules d'arn enzymatiques.
OA09427A (en) "Viral treatment system".
GB9306386D0 (en) Gene expression
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
GB2322131B (en) Improved retroviral vectors for gene therapy
EP0626971A4 (en) Recombinant gibberellin dna and uses thereof.
NO974726L (no) Glucose-induktibel, rekombinant, viral vektor
ZA965494B (en) Therapeutic agents.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020709